<p>Pancreatic cancer stands as one of the most aggressive and deadly malignancies, characterized by a limited array of treatment options and unfavorable patient outcomes. Recent strides in the realm of nanotechnology have introduced advanced approaches to increase the delivery of anti-cancer agents and intensify their effectiveness. The lipid-based nanocarriers have emerged as a focal point of interest for their potential to treat pancreatic cancer. This comprehensive review article offers a thorough analysis of the emerging role played by lipid-based nanocarriers in the management of pancreatic cancer. This review commences with addressing the limitations of the current treatment available for pancreatic cancer. Furthermore, it delves into the array of lipid-based nanocarriers, encompassing liposomes, lipid nanoparticles, and lipid micelles, with a particular emphasis on their advantages concerning drug encapsulation, stability, and biocompatibility. The review also discusses the various strategies adopted to precisely target pancreatic cancer cells, thus enhancing drug delivery, and diminishing systemic toxicity. The exploration extends to the lipid-based nanocarriers’ potential to surmount the hurdles presented by the intricate tumor microenvironment. Lipid-based nanocarriers stand as a propitious pathway for enhancing the treatment of pancreatic cancer, promising a potential breakthrough in ameliorating the daunting clinical obstacles associated with this devastating ailment. The essence of this review is to furnish insights into the current landscape of research, the persisting challenges, and the prospects for the advancement of lipid-based nanocarriers as a valuable augmentation to the therapeutic arsenal combating pancreatic cancer.</p> Graphical Abstract <p></p>